Advertisement
Advertisement
U.S. markets open in 53 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Atreca, Inc. (BCEL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.7900-0.0400 (-2.19%)
At close: 04:00PM EDT
1.8300 +0.04 (+2.23%)
Pre-Market: 07:54AM EDT
Advertisement

Atreca, Inc.

835 Industrial Road
Suite 400
South San Francisco, CA 94070
United States
650 595 2595
https://www.atreca.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees134

Key Executives

NameTitlePayExercisedYear Born
Mr. John A. OrwinPres, CEO & Director889.51kN/A1965
Dr. Tito A. Serafini Ph.D.Founder, Chief Strategy Officer & Director662.77kN/A1963
Mr. Herbert C. CrossChief Financial Officer589.23kN/A1972
Dr. Yann Chong TanChief TechnologistN/AN/AN/A
Dr. Stephen Gould Ph.D.Chief Scientific OfficerN/AN/AN/A
Ms. Courtney J. Phillips J.D.Gen. Counsel & Corp. Sec.N/AN/A1975
Dr. Daniel EmerlingSr. VP of ResearchN/AN/AN/A
Dr. Jonathan Benjamin M.D., Ph.D.Sr. VP of Clinical ResearchN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.

Corporate Governance

Atreca, Inc.’s ISS Governance QualityScore as of June 1, 2022 is 9. The pillar scores are Audit: 7; Board: 9; Shareholder Rights: 10; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement